Medical Scientists Critique Failed Cancer Drugs and Vaccines – Cancer Research Focuses on Revenues, Not Cures

Dr. Mahin Khatami, PhD, is a retired professor and former program director at both the National Institutes of Health (NIH) and National Cancer Institute (NCI). She is a world-renowned cancer researcher and one of the first scientists to link cancer cells to inflammation. Dr. Khatami is also not afraid to criticize the "establishment" in regards to suppressing the truth regarding the integrity of scientific research, where much corruption exists: "The establishment tolerates no challenge or objection from competent and independent scientists. Independent professional views are perceived as a ‘threat’ to the establishment, and professionals become subjected to heavy harassment, bullying, and unethical and criminal practices of retaliation and elimination." This quote is from a December 2016 article by Professor Mahin Khatami, PhD, and published in the journal Clinical and Translational Medicine titled: Safety concerns and hidden agenda behind HPV vaccines: another generation of drug-dependent society? Dr. Khatami has recently co-authored another science-based article exposing conventional oncology’s inability to heal cancer and the folly of cancer vaccines.

Cancer Vaccines: The Next Huge Market for Big Pharma Depends on No Cures for Cancer

The cancer industry is probably the most lucrative business in the United States. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care is $125 billion, with a projected 39 percent increase to $173 billion by 2020. Can you think of any other industry with those kinds of numbers and that kind of expected growth? With the approval of the first cancer vaccine, we are about to see dreams of pharmaceutical companies come true: the wedding of the two most financially lucrative medical sectors, cancer treatment and vaccines. There is just one obvious problem with viewing cancer (or any other disease) as a profitable market for drugs and vaccines: the market value and growth potential is predicated on NOT finding a cure for the disease. Market growth depends on more sick people, not less.